ApicHope Pharmaceutical Group (300723.SZ) subsidiary's innovative drug APH04935 tablets receive U.S. FDA clinical trial approval.

ApicHope Pharmaceutical Group (300723.SZ) announced that recently, its wholly-owned subsidiary Guangzhou ApicHope Pharmaceutical Group Pharmaceutical Co., Ltd. (referred to as "ApicHope Pharmaceutical Group Pharmaceutical") received a letter from the U.S. Food and Drug Administration (FDA) approving the clinical trial of APH04935 tablets, an innovative drug independently developed by the company's subsidiary. APH04935 tablets are a highly active and highly selective small-molecule GLP-1R (full name: Glucagon-like Peptide-1 Receptor) agonist independently developed by the company, targeting to become a once-daily oral small-molecule GLP-1R agonist, intended for weight control and long-term weight management.